Mirtazapine Clinical Suitability — MRCPsych Paper B MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Insomnia, reduced appetite and weight loss
Explanation lettering: D = shown as A · A = shown as C · E = shown as D · C = shown as E
Mirtazapine is particularly useful when depression is accompanied by insomnia, reduced appetite and weight loss. Its histamine H1-antagonist activity is associated with sedation, while increased appetite and weight gain are very common treatment effects. These properties can therefore be advantageous in option B, although daytime sedation and excessive weight gain require monitoring. Options A and C already include increased appetite and weight gain, which mirtazapine may worsen. Option D includes reduced appetite and weight loss, but pre-existing hypersomnia makes additional sedation undesirable. Option E offers no symptom-specific advantage from mirtazapine's sedating and appetite-enhancing profile. Antidepressant selection should still reflect shared decision-making, comorbidity, risk and patient preference.
Reference: Electronic Medicines Compendium, Mirtazapine 45 mg tablets, Summary of Product Characteristics, sections 4.8 and 5.1, revised 2024. https://www.medicines.org.uk/emc/medicine/23045/spc